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Patients with myocardial infarction (MI) are at increased short-term risk of venous 
thromboembolism (VTE). The mechanisms behind this association are unclear. We aimed to 
investigate the impact of acute MI as a transient risk factor for incident VTE while taking 
other concomitant VTE risk factors into account. We conducted a case-crossover study of 
VTE patients (n=707) recruited from the fourth survey of the Tromsø study. VTE risk factors 
and hospitalizations were registered during the 90-day period preceding the VTE diagnosis 
(hazard period) and in four 90-day control periods. Conditional logistic regression was used to 
calculate odds ratios (ORs) with 95% confidence intervals (CIs) for VTE according to acute 
MI and after adjustment for other risk factors. Additionally, we applied a mediation analysis 
to quantify how much the known transient risk factors account for the observed effect of MI 
on VTE risk. MI was recorded in 13 (1.8%) of the hazard periods and in 6 (0.2%) of the 
control periods, which yielded a crude OR of 11.9 (95% CI: 3.9-36.7). Adjustment for 
immobilization and infection yielded an OR of 2.7 (95% CI: 0.6-11.2). The OR was 
attenuated to 2.6 (95% CI: 0.6-11.9) after further adjustment for major surgery, trauma, red 
blood cell transfusion and central venous catheterization. Approximately 60% of the 
association between MI and VTE was mediated through infection and immobilization. In 
conclusion, our findings suggest that the increased VTE risk after MI may to a large extent be 
explained by concomitant conditions related to MI, particularly infections and 
immobilization.   
 






Venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary 
embolism (PE), is a prevalent and potentially fatal cardiovascular disease (1). VTE has been 
acknowledged as the third leading cause of cardiovascular-associated deaths in Western 
countries, after myocardial infarction (MI) and ischemic stroke (2, 3).  
During the last decade, several population-based studies have reported that MI patients 
are at increased risk of subsequent VTE (4-6), especially during the first months after the MI. 
In a large cohort, we recently showed that the short-term risk of VTE after MI was 
particularly pronounced for provoked VTE and PE (6). The pathophysiological mechanisms 
behind the increased risk of VTE after MI are still unclear. Among potentially shared risk 
factors, only advancing age and obesity have been consistently associated with both MI and 
VTE (2, 7, 8). The short-term increase in VTE risk suggests that mechanisms related to the 
MI itself (a direct causal effect) or indirect mechanisms due to hospitalization after MI may 
play a role (9). Heart failure with subsequent left ventricular ejection fraction (LVEF) 
reduction and ultimately venous stasis in the cardiopulmonary circulation could be a direct 
biomechanical mechanism related to the MI that increases VTE risk (10). Moreover, in the 
short time span after the MI, a substantial prothrombotic state with an increase in both 
concentration and activity of circulating coagulation factors has been reported (11-14). Thus, 
MI itself can potentially serve as a trigger for VTE. On the other hand, the short-term risk of 
provoked VTE after MI (6) implies that indirect mechanisms may be important contributors to 
the increased VTE risk. Concomitant presence of transient risk factors for VTE  (e.g. 
infections, immobilization, major surgery, central venous catheter etc.) following an MI could 
result in a short period with particularly high thrombosis risk (15).  
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To what extent an MI serves as a direct trigger for VTE has not been extensively 
investigated. The aim of the present study was therefore to investigate the role of MI as a 
transient risk factor for VTE after accounting for other concomitant VTE risk factors in a 
case-crossover study. A case-crossover design is well-suited for studying transient risk 
factors, because each case serves as his or her own control, and persistent confounders are 
therefore largely controlled for by the design.  
 
Materials and methods  
Study population  
The study population was recruited from the fourth survey of the Tromsø Study (conducted in 
1994/1995), which is a single-center, population-based cohort with repeated health surveys of 
the inhabitants of the municipality of Tromsø, Norway. The Tromsø Study is described in 
detail elsewhere (16). To the fourth survey all inhabitants aged ≥25 years were invited, and 
77% of the eligible population participated. All first lifetime VTE events during follow-up in 
the study population were recorded from the date of enrollment in 1994/95 until December 
31, 2012. The VTE cases were identified by thorough review of hospital and out-patient clinic 
records, as previously described in detail (17). A VTE event was adjudicated when clinical 
signs and symptoms of DVT or PE were combined with an objectively confirmatory 
radiological procedure (e.g. compression ultrasonography, venography, CT, perfusion-
ventilation scan, pulmonary angiography, or autopsy), and resulted in a VTE diagnosis that 
required treatment (e.g. anticoagulant treatment with low-molecular-weight heparin, vitamin 





We used a case-crossover design including all the incident cases of VTE (n=707) occurring 
among the participants of the fourth survey of the Tromsø Study during the period 1994-2012. 
In this design, each participant serves as his/hers own control, and characteristics that do not 
vary within an individual (e.g. history of comorbid conditions, chronic conditions, health 
behaviors, anthropometric measures and inherited thrombophilias) are controlled for through 
the study design (18). The risk period of interest was the 90-day period before the date of 
VTE (hazard period), and exposures during this 90-day period were compared with exposures 
during four preceding 90-day periods (control periods). The length of these hazard and control 
periods was pre-defined based on the definition of provoking factors, as described by Kearon 
et al (19). A wash-out period of 90 days was implemented between the hazard period and 
control periods in order to avoid carry-over effects (18, 20) (Figure 1). For each VTE case, 
trained personnel searched the hospital records for relevant transient risk factors, diagnostic 
procedures, surgical and medical treatment, laboratory tests and diagnosis during hospital 
admission and outpatient clinic visits in any of the hazard or control periods. We did not have 
access to medical records from general practice.  
 
Definition of a transient risk factor 
Transient risk factors were recorded if they were present in the 90-day hazard period or in any 
of the 90-day control periods. MI was defined as the presence of an acute MI diagnosis in the 
medical record. The diagnosis of MI was based on a combination of clinical signs and 
symptoms together with electrocardiography findings and measurements of cardiac enzymes 
in blood samples. Immobilization was defined as the presence of one or more of the following 
characteristics: bedrest for three days or more, ECOG (Eastern Cooperative Oncology Group) 
score of four, or other immobilizing factors specified in the patient’s medical record (e.g. 
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confinement to wheelchair, cast immobilization, etc.).  Infection was recorded if an acute 
infection was noted by a physician in the patient’s medical record. The definition included 
both community-acquired infections that required hospital admission and hospital-acquired 
infections (21). Major surgery, trauma, red blood cell transfusion and use of central venous 
catheter were recorded if described in the medical record. If an exposure occurred over 
several days, it was considered to have occurred if any of the days of the exposure fell within 
the specified 90-day period. 
 
Statistical analysis  
Statistical analyses were performed using STATA version 15.0 (Stata Corporation, College 
Station, TX USA). Conditional logistic regression was used to calculate odds ratios (ORs) 
with 95% confidence intervals (CIs) for VTE according to acute MI and after adjustment for 
other transient risk factors. In Model 1, we calculated the crude OR for the association 
between MI and VTE. In model 2, we adjusted for immobilization and infection since these 
variables are potential transient risk factors for VTE that often co-exist with MI. In model 3, 
we additionally adjusted for other transient VTE risk factors including major surgery, trauma, 
red blood cell transfusion and central venous catheterization (multivariable analysis) by 
entering them simultaneously and one-by-one in the regression model (22). In addition to the 
overall analyses, subgroup analyses were performed for DVT and PE. We also conducted a 
sensitivity analysis where those with a diagnosis of active cancer (n=176) in the hazard period 
were excluded.  
Immobilization and infection can be consequences of MI, and could therefore mediate 
the association between MI and VTE (23). We applied the method developed by Karlson, 
Holm and Breen (KHB-method) to investigate whether and to what extent immobilization and 
infection mediate the relationship between MI and VTE (24-26). The technical details and 
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mathematical proofs of the KHB-method are available elsewhere (25). In brief, this method 
estimates all (e.g., direct, indirect and total) effects on the same scale, and the coefficients in 
the conditional logistic regression models are not affected by rescaling, particularly when the 
total effect is decomposed into the direct and indirect effects (27). This property allows us to 
compare the coefficients without any scale identification issues. Additionally, the KHB-
method has the important feature that it can handle more than one mediator simultaneously 
and it can decompose the contribution from the different mediators while adjusting for other 
factors. The link function clogit (conditional logistic regression) was applied with the hazard- 
or control period as outcome, MI as main exposure, infection and immobilization as mediators 




Characteristics of the study participants are presented in Table 1. Among the 707 VTE cases, 
there were 408 DVTs (57.7%) and 299 PEs (42.3%) with or without concomitant DVT. The 
median age at VTE diagnosis was 71 years and 53.6% were women.  
The distribution of transient risk factors for VTE in the hazard and control periods is 
shown in Table 2. Among the 707 patients, 13 (1.8%) had a diagnosis of MI in the hazard 
period and 6 (0.2%) in a control period. Immobilization occurred in 222 (31.4%) of the hazard 
periods and in 57 (2.0%) of the control periods. Acute infection occurred in 267 (37.8%) of 
the hazard periods and in 107 (3.8%) of the control periods.  
Table 3 shows the frequencies of MI in the hazard and control periods, and the 
corresponding ORs for VTE, DVT and PE. The estimated risk of VTE was high for MI, with 
a crude OR of 11.9 (95% CI: 3.9-36.7). The OR for VTE associated with MI decreased to 2.7 
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(95% CI: 0.6-11.2) after adjustment for immobilization and infection in Model 2. When these 
variables were entered into the model one by one, the OR for VTE associated with MI 
adjusted for immobilization was 8.1 (95% CI: 2.2-30.2) whereas adjustment for infection 
yielded an OR of 3.9 (95% CI: 1.0-14.7). Adding the other VTE risk factors (i.e. major 
surgery, trauma, red blood cell transfusion and central venous catheter) in a third model along 
with immobilization and infection, only marginally attenuated the OR (OR 2.6, 95% CI: 0.6-
11.9) (Table 3, Model 3). 
In subgroup analyses on risk of DVT and PE according to MI status, the results were 
virtually the same as those observed for overall VTE (Table 3). In the crude models, the ORs 
were 14.9 (95% CI: 3.1-70.4) for DVT and 8.9 (95% CI: 0.6-19.6) for PE, respectively. As for 
the overall analyses the associations were substantially attenuated after adjustment for all 
VTE risk factors (Model 3), and the ORs were 2.9 (95% CI: 0.6-19.6) and 1.8 (95% CI: 0.1-
26.9) for DVT and PE, respectively. In the sensitivity analysis, where cases with active cancer 
in the hazard period were excluded (n=176), the ORs did not differ markedly from those of 
the main analyses (Supplementary table 1). 
Furthermore, we analyzed the potential magnitude of the mediating effect of 
immobilization and infection on the relationship between MI and VTE. Table 4 presents the 
mediation analysis adjusted for major surgery, trauma, red blood cell transfusion and central 
venous catheterization. Approximately 60% of the association between MI and VTE was 
mediated through immobilization and infection (Table 4), of which 72% was attributed to 





In the present case-crossover study comprising VTE patients recruited from a general 
population, we aimed to assess the impact of acute MI as a transient risk factor for incident 
VTE. We found that MI was associated with a substantially increased risk of VTE. However, 
the association between MI and VTE was largely attenuated when adjusting for potential 
mediators. The mediation analysis revealed that 60% of the total effect of MI on VTE risk 
was attributed to concomitant infection- and/or immobilization. Our findings suggest that the 
increased short-term risk of VTE associated with MI to a large extent can be explained by the 
presence of other conditions related to the MI, particularly infection and immobilization.  
Despite the fact that several studies have confirmed an association between incident 
MI and risk of venous thrombosis, the mechanisms for this association are uncertain. To our 
knowledge, no previous study has investigated this relationship using a case-crossover design. 
With this design, we confirmed that MI was a transient risk factor for VTE within the first 
three months, but that the main drivers of this increased short-term VTE risk were concurrent 
infection and immobilization. Our findings are in line with a case-control study from Olmsted 
County, which reported that the strength of the association between MI and VTE was 
attenuated after adjustment for all other factors associated with VTE in univariate analyses 
(28).  
Infection can be both a risk factor for MI (29) and a complication following an MI 
(30), and thus could act as both a confounder and a mediator for VTE risk. Unfortunately, the 
temporal sequence between MI and infection could not be determined in our study. 
Nevertheless, our adjustment and mediation analyses indicated that concomitant infection 
(regardless of whether it was a cause or a consequence of the MI) was an important 
contributor to increased VTE risk in patients with MI. A meta-regression analysis based on 36 
studies of risk factors for MI reported that 0.6% (31) of the MIs in the population was 
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attributed to respiratory infections. Serious infections occur in 2-3% of MI patients treated 
with primary percutaneous coronary intervention (PCI) and are associated with an adverse 90-
day outcome and prolonged hospital stay (32). The rate of serious infections after coronary 
artery bypass graft (CABG) surgery ranges from 0.3-4.0% (33). Although the overall rate of 
infections in MI patients appears to be low, infection may still play an important role in VTE-
risk stratification of MI patients. The potential discriminatory power of infection on VTE risk 
should therefore be investigated in a prospective study of MI patients.  
Immobilization is  another recognized risk factor for VTE (34) and appear to be an 
important mediator of VTE risk in MI patients. Infection and immobilization often co-exist 
(21, 35), and the combined exposure has been reported to yield a synergistic effect on VTE 
risk (21). Current guidelines recommend use of thromboprophylaxis with low molecular 
weight heparin (LMWH), low-dose unfractionated heparin or fondaparinux for hospitalized 
acutely ill medical patients throughout the period of immobilization or acute hospital stay (36, 
37). However, since patients with MI are frequently treated with dual antiplatelet therapy in 
the initial phase after coronary intervention (38, 39), their risk of bleeding is additionally 
increased. A risk assessment model that discriminates MI patients at high and low risk of 
VTE is therefore particularly needed to achieve a favorable benefit-to-harm ratio for 
thromboprophylaxis (40-42). Our findings suggest that both infection and immobilization 
should be considered in the development of new risk prediction models for VTE in MI 
patients.   
Even though the risk of VTE in patients with MI was largely explained by other risk 
factors, MI was still associated with an increased risk of VTE after adjustment for all the other 
well-established risk factors for VTE with an OR of 2.6. Potentially, this remaining risk could 
be ascribed to pathophysiological mechanisms related to the MI itself. Heart failure with 
subsequent left ventricular ejection fraction reduction and ultimately stasis in the 
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cardiopulmonary circulation is common after MI (10). Moreover, a prothrombotic state in the 
early phases after an MI (43-45), as well as a persistent coagulation activation long after 
clinical stabilization (13), has been reported.  
Surgery is a strong risk factor for VTE (23). However, further adjustment for surgery 
did not affect the risk estimates in our study, implying that endovascular procedures or CABG 
after MI may not contribute to the risk of VTE in the absence of infection and immobilization.  
Strengths of our study include the case-crossover design with unselected VTE patients, 
which enabled us to focus on transient risk factors while controlling for potential persistent 
confounders such as inherited thrombophilias, chronic conditions and anthropometric 
measures. Our study has some limitations. Even if fixed confounders are controlled for 
through the study design, the presence of residual confounding cannot be ruled out as other 
unmeasured or unknown transient risk factors could have influenced the association between 
MI and VTE. In addition, we cannot rule out that comorbidities related to risk of both MI and 
VTE has developed during the 1.5 year follow-up. Furthermore, surveillance bias might have 
occurred, as physicians could be more aware of VTE risk factors when VTE is suspected than 
during admission for other conditions in the control periods. If so, this would lead to an 
overestimation of the impact of such risk factors on the risk of VTE (21), potentially resulting 
in an over-adjustment of the association between MI and VTE. The temporal sequence 
between MI and exposure to the other risk factors could not fully be determined, and 
unfortunately, we could not distinguish whether immobilization and infection acted as 
confounders or mediators of the association between MI and VTE. Hence, a prospective 
cohort of MI patients is warranted to study the temporal sequence between exposure, 
intermediates and outcome. Information on MI-exposure was based on review of medical 
records with no further outcome validation. However, exposure misclassification is unlikely 
due to the fact that a diagnosis of MI is based on a combination of objective criteria from 
12 
 
electrocardiography findings and measurements of cardiac enzymes in blood samples together 
with clinical signs and symptoms (46). Lastly, due to the small sample size and some wide 
confidence intervals, our estimates must be interpreted with caution.  
In conclusion, our findings suggest that the increased short-term risk of VTE after MI 
to a large extent may be explained by concomitant conditions related to the MI, particularly 
infections and immobilization.  
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Table 1 Characteristics of the study participants  
 At time of VTE diagnosis (n=707) 
Median age (years±SD) 71 ± 14 
Female sex (n, %) 379 (53.6) 
  
Deep vein thrombosis (n, %) 408 (57.7) 
Pulmonary embolism* (n, %) 299 (42.3) 
Values are absolute numbers (n) with percentages of total hazard/control periods 
*Pulmonary embolism with or without concomitant deep vein thrombosis  
 
 
Table 2 The distribution of transient risk factors for VTE in the hazard and control periods 




MI (Myocardial infarction) (n, %) 13 (1.8) 6 (0.2) 
Immobilization (n, %) † 222 (31.4) 57 (2.0) 
Infection (n, %) 267 (37.8) 107 (3.8) 
Major surgery (n, %)  118 (16.7) 88 (3.1) 
Red blood cell transfusion (n, %) 82 (11.6) 28 (1.0) 
Trauma (e.g. fracture) (n, %)  71 (10.0) 25 (0.9) 
Central venous catheter (n, %) 56 (7.9) 17 (0.6) 
Values are absolute numbers (n) with percentages of total hazard/control periods  












Table 3 Distribution of MI in the hazard and control periods and odds ratios (ORs) of venous 
thromboembolism, deep vein thrombosis and pulmonary embolism    




OR (95% CI) 
Model 2 
OR (95% CI) 
Model 3 
OR (95% CI) 
VTE n=707a n=2828    
MI 13 (1.8) 6 (0.2) 11.9 (3.9-36.7) 2.7 (0.6-11.2) 2.6 (0.6-11.9) 
DVT n=408b n=1632    
MI 8 (2.0) 3 (0.2) 14.9 (3.1-70.4) 3.3 (0.6-19.6) 2.9 (0.5-17.8) 
PE n=299b n=1196    
MI 5 (1.7) 3 (0.3) 8.9 (1.7-46.7) 2.0 (0.2-22.5) 1.8 (0.1-26.9) 
CI, confidence interval; OR, odds ratio   
The reference category was “no MI” 
a707 venous thrombosis cases, four control periods for each case 
b408 deep vein thrombosis-cases, four control periods for each case; 299 pulmonary embolism cases, 
four control periods for each case 
Model 1: Unadjusted odd ratio 
Model 2: Adjusted for infection and immobilization 
Model 3: Adjusted as in Model 2 with addition of major surgery, trauma, red blood cell transfusion 






Table 4 The KHB mediation analysis (24, 25) and decomposition results for the association between 
MI and VTE 
 Conditional logistic regression  
 Coefficient SE Mediation percentage 
Coefficients    
Total effect 2.43 0.77 - 
Direct effect 0.96 0.77 - 
Mediating effect 1.47* 0.71 60.5 
Through    
  Infection 1.06 0.28 71.8 
  Immobilization 0.42 0.35 28.2 
*p<0.005  
 
